Caforio M, Tumino N, Sorino C, Manni I, Di Giovenale S, Piaggio G
Front Immunol. 2023; 14:1191908.
PMID: 37435061
PMC: 10332273.
DOI: 10.3389/fimmu.2023.1191908.
Cifaldi L, Melaiu O, Giovannoni R, Benvenuto M, Focaccetti C, Nardozi D
Front Immunol. 2023; 14:1197053.
PMID: 37359555
PMC: 10285446.
DOI: 10.3389/fimmu.2023.1197053.
Valenzuela-Vazquez L, Nunez-Enriquez J, Sanchez-Herrera J, Medina-Sanson A, Perez-Saldivar M, Jimenez-Hernandez E
Front Oncol. 2022; 12:1023510.
PMID: 36419901
PMC: 9677112.
DOI: 10.3389/fonc.2022.1023510.
Damele L, Spaggiari G, Parodi M, Mingari M, Vitale M, Vitale C
Cancers (Basel). 2022; 14(18).
PMID: 36139598
PMC: 9496735.
DOI: 10.3390/cancers14184439.
Maddineni S, Silberstein J, Sunwoo J
J Immunother Cancer. 2022; 10(5).
PMID: 35580928
PMC: 9115029.
DOI: 10.1136/jitc-2022-004693.
From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment.
Kloss S, Dehmel S, Braun A, Parnham M, Kohl U, Schiffmann S
Front Immunol. 2020; 11:1423.
PMID: 32733473
PMC: 7360838.
DOI: 10.3389/fimmu.2020.01423.
Harnessing NK Cell Checkpoint-Modulating Immunotherapies.
Chauhan S, Koehl U, Kloess S
Cancers (Basel). 2020; 12(7).
PMID: 32640575
PMC: 7408278.
DOI: 10.3390/cancers12071807.
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma.
Swan D, Lynch K, Gurney M, ODwyer M
Ther Adv Hematol. 2019; 10:2040620719854171.
PMID: 31244984
PMC: 6582283.
DOI: 10.1177/2040620719854171.
Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).
Falco M, Pende D, Munari E, Vacca P, Mingari M, Moretta L
HLA. 2019; 93(4):185-194.
PMID: 30828978
PMC: 6767140.
DOI: 10.1111/tan.13509.
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.
Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L
Front Immunol. 2017; 8:1444.
PMID: 29163516
PMC: 5682004.
DOI: 10.3389/fimmu.2017.01444.
Control of NK Cell Activation by Immune Checkpoint Molecules.
Beldi-Ferchiou A, Caillat-Zucman S
Int J Mol Sci. 2017; 18(10).
PMID: 29023417
PMC: 5666811.
DOI: 10.3390/ijms18102129.
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.
Kloess S, Ede Valverde da Silva A, Oberschmidt O, Gardlowski T, Matthies N, Vyas M
Front Immunol. 2017; 8:1100.
PMID: 28943878
PMC: 5596090.
DOI: 10.3389/fimmu.2017.01100.
Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor.
Pesce S, Moretta L, Moretta A, Marcenaro E
Front Immunol. 2016; 7:414.
PMID: 27774094
PMC: 5053980.
DOI: 10.3389/fimmu.2016.00414.
A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.
Vasu S, Berg M, Davidson-Moncada J, Tian X, Cullis H, Childs R
Cytotherapy. 2015; 17(11):1582-93.
PMID: 26432560
PMC: 7241296.
DOI: 10.1016/j.jcyt.2015.07.020.
Natural killer cell receptors: alterations and therapeutic targeting in malignancies.
Konjevic G, Vuletic A, Mirjacic Martinovic K
Immunol Res. 2015; 64(1):25-35.
PMID: 26374324
DOI: 10.1007/s12026-015-8695-4.
Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.
Nalle S, Turner J
Mucosal Immunol. 2015; 8(4):720-30.
PMID: 25943273
DOI: 10.1038/mi.2015.40.
KIR3DL1 genetic diversity and phenotypic variation in the Chinese Han population.
Tao S, He Y, Ying Y, He J, Zhu F, Lv H
Genes Immun. 2013; 15(1):8-15.
PMID: 24173144
DOI: 10.1038/gene.2013.55.
Natural killer cell biology: an update and future directions.
Campbell K, Hasegawa J
J Allergy Clin Immunol. 2013; 132(3):536-544.
PMID: 23906377
PMC: 3775709.
DOI: 10.1016/j.jaci.2013.07.006.
Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy.
Kang L, Voskinarian-Berse V, Law E, Reddin T, Bhatia M, Hariri A
Front Immunol. 2013; 4:101.
PMID: 23641243
PMC: 3640206.
DOI: 10.3389/fimmu.2013.00101.
T cell depleted haploidentical transplantation: positive selection.
Aversa F
Pediatr Rep. 2011; 3 Suppl 2:e14.
PMID: 22053276
PMC: 3206540.
DOI: 10.4081/pr.2011.s2.e14.